Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
The COVID-19 disease is an unprecedented international public health emergency and considerably impacts the global economy and health service system. While awaiting the development of an effective vaccine, searching for the therapy for severe or critical COVID-19 patients is essential for reducing t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-10-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2020.571597/full |
| _version_ | 1819171355516469248 |
|---|---|
| author | Danfei Liu Tongyue Zhang Yijun Wang Limin Xia |
| author_facet | Danfei Liu Tongyue Zhang Yijun Wang Limin Xia |
| author_sort | Danfei Liu |
| collection | DOAJ |
| description | The COVID-19 disease is an unprecedented international public health emergency and considerably impacts the global economy and health service system. While awaiting the development of an effective vaccine, searching for the therapy for severe or critical COVID-19 patients is essential for reducing the mortality and alleviating the tension of the health service system. Cytokine release syndrome (CRS) induced by elevated interleukin-6 was recognized to underscore the pathology of severe COVID-19 patients. Inhibiting CRS by agents suppressing IL-6 may relieve symptoms, shorten the hospital stay and reduce the need for oxygen therapy. Although evidence from randomized, double-blinded clinical trials is still lacking, the IL-6R inhibitor tocilizumab (TCZ) has shown some clinical benefits in the treatment of severe COVID-19 patients and have been included in clinical guidelines. In this review, we focused on the possible mechanisms of TCZ in the treatment of CRS and highlighted some significant considerations in the use of TCZ to treat COVID-19 patients. |
| first_indexed | 2024-12-22T19:49:58Z |
| format | Article |
| id | doaj.art-1dae5df3b2744a2e9929d91299ccc11c |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-22T19:49:58Z |
| publishDate | 2020-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-1dae5df3b2744a2e9929d91299ccc11c2022-12-21T18:14:34ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2020-10-01710.3389/fmed.2020.571597571597Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?Danfei LiuTongyue ZhangYijun WangLimin XiaThe COVID-19 disease is an unprecedented international public health emergency and considerably impacts the global economy and health service system. While awaiting the development of an effective vaccine, searching for the therapy for severe or critical COVID-19 patients is essential for reducing the mortality and alleviating the tension of the health service system. Cytokine release syndrome (CRS) induced by elevated interleukin-6 was recognized to underscore the pathology of severe COVID-19 patients. Inhibiting CRS by agents suppressing IL-6 may relieve symptoms, shorten the hospital stay and reduce the need for oxygen therapy. Although evidence from randomized, double-blinded clinical trials is still lacking, the IL-6R inhibitor tocilizumab (TCZ) has shown some clinical benefits in the treatment of severe COVID-19 patients and have been included in clinical guidelines. In this review, we focused on the possible mechanisms of TCZ in the treatment of CRS and highlighted some significant considerations in the use of TCZ to treat COVID-19 patients.https://www.frontiersin.org/articles/10.3389/fmed.2020.571597/fullCOVID-19cytokine release syndromeinterleukin-6tocilizumabSARS-CoV-2 |
| spellingShingle | Danfei Liu Tongyue Zhang Yijun Wang Limin Xia Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? Frontiers in Medicine COVID-19 cytokine release syndrome interleukin-6 tocilizumab SARS-CoV-2 |
| title | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? |
| title_full | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? |
| title_fullStr | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? |
| title_full_unstemmed | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? |
| title_short | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? |
| title_sort | tocilizumab the key to stop coronavirus disease 2019 covid 19 induced cytokine release syndrome crs |
| topic | COVID-19 cytokine release syndrome interleukin-6 tocilizumab SARS-CoV-2 |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2020.571597/full |
| work_keys_str_mv | AT danfeiliu tocilizumabthekeytostopcoronavirusdisease2019covid19inducedcytokinereleasesyndromecrs AT tongyuezhang tocilizumabthekeytostopcoronavirusdisease2019covid19inducedcytokinereleasesyndromecrs AT yijunwang tocilizumabthekeytostopcoronavirusdisease2019covid19inducedcytokinereleasesyndromecrs AT liminxia tocilizumabthekeytostopcoronavirusdisease2019covid19inducedcytokinereleasesyndromecrs |